Trexquant Investment LP Purchases 50,758 Shares of Abeona Therapeutics Inc. $ABEO

Key Points

• Trexquant Investment LP increased its stake in Abeona Therapeutics by 74.1%, now owning 119,274 shares valued at approximately $568,000.
• Several institutional investors have recently made significant moves, with 80.56% of Abeona Therapeutics' stock now held by such investors.
• Abeona Therapeutics reported an earnings per share of $1.71 for the last quarter, significantly exceeding analysts' estimates of a loss of ($0.39).

Trexquant Investment LP boosted its stake in Abeona Therapeutics Inc. (NASDAQ:ABEO - Free Report) by 74.1% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 119,274 shares of the biopharmaceutical company's stock after purchasing an additional 50,758 shares during the period. Trexquant Investment LP owned about 0.24% of Abeona Therapeutics worth $568,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of ABEO. Western Standard LLC increased its holdings in Abeona Therapeutics by 22.8% in the fourth quarter. Western Standard LLC now owns 2,084,418 shares of the biopharmaceutical company's stock valued at $11,610,000 after purchasing an additional 386,321 shares during the period. Jane Street Group LLC grew its holdings in Abeona Therapeutics by 894.8% during the 4th quarter. Jane Street Group LLC now owns 131,478 shares of the biopharmaceutical company's stock worth $732,000 after acquiring an additional 118,262 shares during the period. Wellington Management Group LLP acquired a new stake in shares of Abeona Therapeutics in the 4th quarter valued at about $520,000. OMERS ADMINISTRATION Corp acquired a new stake in shares of Abeona Therapeutics in the 4th quarter valued at about $362,000. Finally, Schonfeld Strategic Advisors LLC acquired a new stake in shares of Abeona Therapeutics in the 4th quarter valued at about $341,000. 80.56% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities analysts recently weighed in on ABEO shares. Stifel Nicolaus dropped their price target on shares of Abeona Therapeutics from $21.00 to $20.00 and set a "buy" rating on the stock in a research report on Friday, May 16th. Oppenheimer lifted their target price on shares of Abeona Therapeutics from $19.00 to $20.00 and gave the stock an "outperform" rating in a research report on Friday, August 15th. Finally, HC Wainwright restated a "buy" rating and set a $20.00 price target on shares of Abeona Therapeutics in a research note on Monday, August 18th. Five equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus price target of $19.50.

Abeona Therapeutics Price Performance

NASDAQ:ABEO traded down $0.32 during midday trading on Friday, hitting $6.43. The company had a trading volume of 1,181,379 shares, compared to its average volume of 646,639. Abeona Therapeutics Inc. has a 52-week low of $3.93 and a 52-week high of $7.54. The stock's fifty day moving average price is $6.59 and its 200-day moving average price is $5.90. The company has a market capitalization of $329.72 million, a PE ratio of 9.19 and a beta of 1.67. The company has a quick ratio of 6.65, a current ratio of 6.73 and a debt-to-equity ratio of 0.09.

Abeona Therapeutics (NASDAQ:ABEO - Get Free Report) last announced its earnings results on Thursday, August 14th. The biopharmaceutical company reported $1.71 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.39) by $2.10. The company had revenue of $0.40 million during the quarter, compared to analysts' expectations of $21.71 million. As a group, research analysts expect that Abeona Therapeutics Inc. will post -1.16 earnings per share for the current year.

Insider Buying and Selling at Abeona Therapeutics

In other Abeona Therapeutics news, Director Faith L. Charles sold 10,738 shares of the company's stock in a transaction dated Wednesday, July 9th. The shares were sold at an average price of $5.86, for a total transaction of $62,924.68. Following the completion of the sale, the director directly owned 139,094 shares in the company, valued at $815,090.84. This represents a 7.17% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CEO Vishwas Seshadri sold 69,420 shares of the company's stock in a transaction dated Wednesday, July 9th. The shares were sold at an average price of $5.86, for a total transaction of $406,801.20. Following the sale, the chief executive officer owned 1,234,341 shares of the company's stock, valued at approximately $7,233,238.26. The trade was a 5.32% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 150,685 shares of company stock valued at $884,186. 6.90% of the stock is currently owned by insiders.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.